{"id":47289,"date":"2009-11-23T13:06:38","date_gmt":"2009-11-23T18:06:38","guid":{"rendered":"tag:www.hepatitis-central.com,2009:\/mt\/\/1.738"},"modified":"2009-11-23T14:00:07","modified_gmt":"2009-11-23T19:00:07","slug":"hepatitis-c-study-demonstrates-potential-for-therapeutic-vaccine","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/47289","title":{"rendered":"Hepatitis C Study Demonstrates Potential for Therapeutic Vaccine"},"content":{"rendered":"<p>A recent study revealed that a therapeutic vaccine combined with a topical immune-enhancing agent initiated an immune response against the Hepatitis C virus.<\/p>\n<p>Hep C Therapeutic Vaccine Shows Hints of Efficacy<\/p>\n<p>November 18, 2009<\/p>\n<p>A hepatitis C virus (HCV) therapeutic vaccine&#8211;designed to boost immune control of the virus in people already infected with HCV&#8211;has demonstrated that such an approach might work, according to a study presented at the American Association for the Study of Liver Disease (AASLD) Conference in Boston, and reported by aidsmap.<\/p>\n<p>Because HCV mutates so easily, some experts have claimed that it might be impossible to develop a successful preventive vaccine for it. Others, however, have hoped that it might be possible to trigger the body to better control or ward off HCV infection.<\/p>\n<p>Continue reading the entire article:<br \/>\n<a href=\"http:\/\/www.aidsmeds.com\/articles\/hiv_hcv_vaccine_1667_17601.shtml\">http:\/\/www.aidsmeds.com\/articles\/hiv_hcv_vaccine_1667_17601.shtml<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A recent study revealed that a therapeutic vaccine combined with a topical immune-enhancing agent initiated an immune response against the Hepatitis C virus. Hep C Therapeutic Vaccine Shows Hints of Efficacy November 18, 2009 A hepatitis C virus (HCV) therapeutic vaccine&#8211;designed to boost immune control of the virus in people already infected with HCV&#8211;has demonstrated [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-47289","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/47289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=47289"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/47289\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=47289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=47289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=47289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}